These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32935910)

  • 21. The challenges and opportunities of traditional Chinese medicines against COVID-19: a way out from a network perspective.
    Zuo HL; Lin YC; Huang HY; Wang X; Tang Y; Hu YJ; Kong XJ; Chen QJ; Zhang YZ; Hong HC; Li J; Hu SY; Huang HD
    Acta Pharmacol Sin; 2021 Jun; 42(6):845-847. PubMed ID: 33850275
    [No Abstract]   [Full Text] [Related]  

  • 22. CD147 inhibitors as a treatment for melanoma: Promising agents against SARS-CoV-2 infection.
    Pourani MR; Nekooghadam SM; Youssefian L; Vahidnezhad H; Abdollahimajd F
    Dermatol Ther; 2020 Nov; 33(6):e14449. PubMed ID: 33098610
    [No Abstract]   [Full Text] [Related]  

  • 23. A case of COVID-19 with papulovesicular rash that progressed to retiform purpura, accompanied by cherry angiomas.
    Agirgol S; Çaytemel C; Kolan AŞ; Vural H
    Sao Paulo Med J; 2021; 139(2):186-189. PubMed ID: 33566880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statins as candidate therapeutic agents for coronavirus disease 2019 (COVID-19).
    Li SD; Zhang SY; Peng B
    Chin Med J (Engl); 2020 Nov; 134(4):407-409. PubMed ID: 33617183
    [No Abstract]   [Full Text] [Related]  

  • 25. Ensuring continued progress for development of COVID-19 therapeutics in children.
    Noel GJ; DeBiasi RL; Crandall W; Connor EM
    Pediatr Res; 2021 Dec; 90(6):1112-1114. PubMed ID: 33603214
    [No Abstract]   [Full Text] [Related]  

  • 26. Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia.
    Conte WL
    Mult Scler Relat Disord; 2020 Sep; 44():102315. PubMed ID: 32593144
    [No Abstract]   [Full Text] [Related]  

  • 27. An epigenetic signature to fight COVID-19.
    Herbein G
    EBioMedicine; 2021 May; 67():103385. PubMed ID: 33993054
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-COVID treatments: why the world is still waiting.
    Ledford H
    Nature; 2022 Aug; 608(7922):258-260. PubMed ID: 35945375
    [No Abstract]   [Full Text] [Related]  

  • 29. Coronavirus disease 2019 in a psoriatic patient with concomitant chronic obstructive pulmonary disease under treatment with risankizumab.
    Kiss N; Lőrincz K; Medvecz M; Fésűs L; Csuha P; Hermányi Z; Wikonkál NM
    Dermatol Ther; 2020 Nov; 33(6):e14186. PubMed ID: 32794375
    [No Abstract]   [Full Text] [Related]  

  • 30. Implication of nanotechnology-based approaches to combat SARS-CoV-2 infection.
    Heidari M; Salmanpour M; Tamaddon AM
    Indian J Pharmacol; 2021; 53(1):78-79. PubMed ID: 33976004
    [No Abstract]   [Full Text] [Related]  

  • 31. The red half-moon nail sign: a novel manifestation of coronavirus infection.
    Neri I; Guglielmo A; Virdi A; Gaspari V; Starace M; Piraccini BM
    J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):e663-e665. PubMed ID: 32535979
    [No Abstract]   [Full Text] [Related]  

  • 32. COVID-19 and nail manifestation: be on the lookout for the red half-moon nail sign.
    Méndez-Flores S; Zaladonis A; Valdes-Rodriguez R
    Int J Dermatol; 2020 Nov; 59(11):1414. PubMed ID: 32860426
    [No Abstract]   [Full Text] [Related]  

  • 33. Skin manifestations of SARS-CoV-2 Omicron variant: Clinical, pathological, and immunological insights.
    Zhang Y; Mu Y; Han B; Albarmaqi RA; Wang H; Zhao Y; Tian Z; Xia J; Li S; Wang H; Fu A; Zheng H; Tian Y
    J Eur Acad Dermatol Venereol; 2024 Aug; 38(8):e654-e657. PubMed ID: 38545895
    [No Abstract]   [Full Text] [Related]  

  • 34. Introduction to the Special Section: COVID-19 - insights on pharmacology and pharmacotherapy.
    Sanak M
    Pharmacol Rep; 2020 Dec; 72(6):1445. PubMed ID: 33206322
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.
    Gautret P; Lagier JC; Honoré S; Hoang VT; Raoult D
    Int J Antimicrob Agents; 2021 Jan; 57(1):106242. PubMed ID: 33408033
    [No Abstract]   [Full Text] [Related]  

  • 36. Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.
    Nguyen TV
    Int J Antimicrob Agents; 2021 Jan; 57(1):106169. PubMed ID: 33408026
    [No Abstract]   [Full Text] [Related]  

  • 37. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.
    Gautret P; Lagier JC; Honoré S; Hoang VT; Colson P; Raoult D
    Int J Antimicrob Agents; 2021 Jan; 57(1):106243. PubMed ID: 33408014
    [No Abstract]   [Full Text] [Related]  

  • 38. Could Artesunate Have a Positive Effect on the Neurological Complications Related to Infection When It Is Used in the Treatment of COVID-19?
    Uzun T; Toptaş O; Aydın Türkoğlu Ş
    ACS Chem Neurosci; 2020 Dec; 11(24):4001-4006. PubMed ID: 33269910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How to manage high-risk asymptomatic COVID-19 carriers; COVID-19 poses a huge threat to public health and to dermatology specialty as well.
    Kassir M; Gupta M; Abdelmaksoud A; Goldust M
    Dermatol Ther; 2020 Nov; 33(6):e14064. PubMed ID: 32710581
    [No Abstract]   [Full Text] [Related]  

  • 40. Update to living systematic review on drug treatments for covid-19.
    BMJ; 2020 Dec; 371():m4852. PubMed ID: 33334735
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.